Feasibility and Usability of a Chest-Strap Ambulatory ECG Monitor in Active Individuals in Comparison With a Traditional Ambulatory ECG Patch Monitor (MoMe ARC)
14. september 2026 oppdatert av: Elizabeth H. Dineen, Mayo Clinic
The purpose of this research is to compare the standard ambulatory ECG monitor, the MoMe ARC, against Fourth Frontier's "Frontier X Plus".
This device is an FDA-Cleared chest-strap-based ECG wearable that provides an alternative modality to capture ambulatory ECG rhythm changes.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Studietype
Observasjonsmessig
Registrering (Antatt)
15
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Elizabeth Dineen, DO
- Telefonnummer: 904-953-5230
- E-post: dineen.elizabeth@mayo.edu
Studiesteder
-
-
Arizona
-
Scottsdale, Arizona, Forente stater, 85259
- Rekruttering
- Mayo Clinic Arizona
-
Ta kontakt med:
- Satyajit Reddy, MD
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32224
- Rekruttering
- Mayo Clinic Florida
-
Ta kontakt med:
- Elizabeth Dineen, DO
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Rekruttering
- Mayo Clinic Rochester
-
Ta kontakt med:
- Kathryn Larson, MD
- Telefonnummer: 507-293-6358
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Active adults older than 22 years who participate in moderate- to high-intensity exercise at least 4 days per week and more than 150 minutes per week total, and who have been prescribed ambulatory ECG monitoring for clinical purposes for 24 hours or more.
Beskrivelse
Inclusion Criteria:
- Adult participants (>22 years; Frontier X is approved for use in this age group) who participate in >4 days a week of >150 minutes total per week of moderate to high intensity exercise who were prescribed a ambulatory ECG monitor for clinical purposes for 24 hours or more.
- Patients must agree to wear the Frontier X monitor for the prescribed duration and use the Frontier X Plus application
Exclusion Criteria:
- Current use of Implanted Cardiac Devices
- Pregnancy
- Known allergies to any of the materials listed in the "List of Patient-Contacting Materials"
- Presence of skin injuries or broken skin in the area where the chest strap is worn
- Inability to use a compatible mobile device required for the operation of the study device
- Any cognitive or physical limitations that, in the opinion of the investigator, limits the participant's ability to fully follow study procedures
- Medical restrictions on exercise for safety including cardiac, orthopedic or other relevant past medical history
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Active Adults Undergoing Ambulatory ECG Monitoring
Participants prescribed clinical ambulatory ECG monitoring will wear the Frontier X Plus chest-strap ECG device simultaneously with the MoMe ARC traditional ambulatory ECG monitor during their prescribed monitoring period and typical daily activities, including exercise.
|
The Frontier X Plus is a chest-strap-based wearable ECG device with embedded dry electrodes and a sensor that captures, stores, analyzes, and transmits ECG data through a mobile application and cloud-based platform for subsequent review.
The MoMe ARC monitor will be used as the traditional ambulatory ECG comparator and processed according to standard clinical workflows.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Concordance of Symptomatic Triggered Events Between Frontier X Plus and MoMe ARC
Tidsramme: 24 hours
|
Automated Holter-style reports generated from the Frontier X Plus device will be compared with MoMe ARC reports.
Concordance will be assessed for symptomatic triggered events.
Results will be reported as the number of symptomatic triggered event findings for which the Frontier X Plus and MoMe ARC reports are in agreement.
|
24 hours
|
|
Concordance of Ventricular Tachycardia Episodes Greater Than 3 Beats Detected by Frontier X Plus and MoMe ARC
Tidsramme: 24 hours
|
Automated Holter-style reports generated from the Frontier X Plus device will be compared with MoMe ARC reports.
Concordance will be assessed for ventricular tachycardia episodes greater than 3 beats.
Results will be reported as the number of ventricular tachycardia episode findings for which the Frontier X Plus and MoMe ARC reports are in agreement.
|
24 hours
|
|
Concordance of Supraventricular Tachycardia Episodes Greater Than 3 Beats Between Frontier X Plus and MoMe ARC
Tidsramme: 24 hours
|
Automated Holter-style reports generated from the Frontier X Plus device will be compared with MoMe ARC reports.
Concordance will be assessed for supraventricular tachycardia episodes greater than 3 beats.
Results will be reported as the number of supraventricular tachycardia episode findings for which the Frontier X Plus and MoMe ARC reports are in agreement.
|
24 hours
|
|
Total Time in Atrial Fibrillation Detected by Frontier X Plus and MoMe ARC
Tidsramme: 24 hours
|
Automated Holter-style reports generated from the Frontier X Plus device will be compared with MoMe ARC reports.
Total time in atrial fibrillation will be assessed for each device and reported as the cumulative duration of atrial fibrillation detected during the concordant monitoring period.
|
24 hours
|
|
Concordance of Premature Atrial Contraction Counts Between Frontier X Plus and MoMe ARC
Tidsramme: 24 hours
|
Automated Holter-style reports generated from the Frontier X Plus device will be compared with MoMe ARC reports.
Concordance will be assessed for premature atrial contraction counts.
Results will be reported as the number of premature atrial contraction count findings for which the Frontier X Plus and MoMe ARC reports are in agreement.
|
24 hours
|
|
Concordance of Premature Ventricular Contraction Counts Between Frontier X Plus and MoMe ARC
Tidsramme: 24 hours
|
Automated Holter-style reports generated from the Frontier X Plus device will be compared with MoMe ARC reports.
Concordance will be assessed for premature ventricular contraction counts.
Results will be reported as the number of premature ventricular contraction count findings for which the Frontier X Plus and MoMe ARC reports are in agreement.
|
24 hours
|
|
Atrial Fibrillation Burden Detected by Frontier X Plus and MoMe ARC
Tidsramme: 24 hours
|
Automated Holter-style reports generated from the Frontier X Plus device will be compared with MoMe ARC reports.
Atrial fibrillation burden will be assessed for each device and reported as the percentage of the concordant monitoring period during which atrial fibrillation was detected.
|
24 hours
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Elizabeth Dineen, DO, Mayo Clinic
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. september 2026
Primær fullføring (Antatt)
23. februar 2027
Studiet fullført (Antatt)
23. februar 2027
Datoer for studieregistrering
Først innsendt
14. august 2026
Først innsendt som oppfylte QC-kriteriene
14. august 2026
Først lagt ut (Faktiske)
19. august 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
17. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. september 2026
Sist bekreftet
1. september 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 25-012842
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Ja
produkt produsert i og eksportert fra USA
Ja
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .